Evidence map›Paper›PMID 28005927›Full record

ArticlePloS one2016

Antiproliferative and Pro-Apoptotic Effects of MiR-4286 Inhibition in Melanoma Cells.

Anna Komina, Nadezhda Palkina, Mariya Aksenenko, Seseg Tsyrenzhapova, Tatiana Ruksha

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 47 citations in OpenAlex.

  1. Trial
  2. Article
  3. Chemotherapy Supports Cancer Cell Dissemination in a Melanoma Preclinical Model.Asian Pacific journal of cancer prevention : APJCP · 2026
    Article
  4. Article
  5. Review
  6. Article
  7. Apelin/APJ: Another Player in the Cancer Biology Network.International journal of molecular sciences · 2025
    Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. miRNAs in the Diagnosis and Prognosis of Skin Cancer.Frontiers in cell and developmental biology · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Anna KominaDepartment of Pathophysiology, Krasnoyarsk State Medical University, Krasnoyarsk, Russian Federation.
Nadezhda PalkinaDepartment of Pathophysiology, Krasnoyarsk State Medical University, Krasnoyarsk, Russian Federation.
Mariya AksenenkoDepartment of Pathophysiology, Krasnoyarsk State Medical University, Krasnoyarsk, Russian Federation.
Seseg TsyrenzhapovaDepartment of Pathophysiology, Krasnoyarsk State Medical University, Krasnoyarsk, Russian Federation.
Tatiana RukshaDepartment of Pathophysiology, Krasnoyarsk State Medical University, Krasnoyarsk, Russian Federation.
Krasnoyarsk State Medical University · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionMicroRNAs are essential regulators of gene expression at the post-transcriptional level. Their expression is altered in cancer tissues, and evaluation of these alterations is considered a promising tool used to diagnose and identify prognostic markers. MATERIALS AND

methodsThe microRNA expression profiles of formalin-fixed, paraffin-embedded melanoma and melanocytic nevi samples were estimated with a microarray and subsequently validated by real-time PCR. Melanoma cells were transfected with miR-4286 inhibitor to evaluate the influence of this microRNA on the viability, proliferation, apoptosis, migration, and invasion of melanoma cells.

resultsThe microarray revealed that the expression of 1,171 microRNAs was altered in melanoma samples compared to melanocytic nevi. Real-time PCR validation experiments found the microRNA expression levels to correspond to the melanoma/melanocytic nevi microarray results. The pathway analysis identified 52 modulated pathways in melanoma. Moreover, the application of miR-4286 inhibitor to BRO melanoma cells resulted in a 2.6-fold increase in the apoptosis rate and a 1.7-fold decrease in the cell proliferation/viability but did not affect the invasiveness and migration of these cells. Furthermore, the use of miR-4286 inhibitor altered the mRNA expression of several miR-4286 gene targets: folylpolyglutamate synthase, RNA polymerase I-specific transcription initiation factor, apelin, G-protein-coupled receptor 55, and high-mobility group A1 protein, which have been implicated in cell proliferation/apoptosis regulation. Lastly, the transiently transfected SK-MEL-1 cells with miR-4286 inhibitor decreased proliferation rate and modulated folylpolyglutamate synthase rates of these cells.

conclusionOur results demonstrate that miR-4286 mediates proliferation and apoptosis in melanoma cells, these findings may represent a novel mechanism underlying these processes.

Indexed as

ApoptosisCell ProliferationGene Expression Regulation, NeoplasticAdultAgedAged, 80 and overBiomarkers, TumorCell MovementFemaleHumansMaleMelanomaMicroRNAsMiddle AgedNeoplasm InvasivenessNeoplasm StagingBiomarkers, TumorMicroRNAsMIRN-4286 microRNA, human

Identifiers

PMID28005927
PMCPMC5179095
OpenAlexW2570908417

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.